iShares MSCI Taiwan ETF vs uniQure N.V. Ordinary Shares — how do they compare? iShares MSCI Taiwan ETF trades at $108.02 (market cap $12.16B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.45B). The key difference: iShares MSCI Taiwan ETF is far larger — about 8.4× uniQure N.V. Ordinary Shares's market cap, and iShares MSCI Taiwan ETF is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Taiwan ETF for 53 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| EWT | QURE | |
|---|---|---|
Market Cap | $12.16B | $1.45B |
Volume | 3,390,174 | 3,323,243 |
Sector | Broad Market / Factor | Health |
52-Week High | $118.00 | $70.59 |
52-Week Low | $60.03 | $9.03 |
Typical Hold Time | 53 Days | 0 Days |
Enterprise Value | — | $707.46M |
Signals from Pluang's Aura AI — not financial advice
EWT (iShares MSCI Taiwan ETF) trades at $113.46, down 0.71% on the day, with technical indicators showing a bullish trend from moving averages while oscillators remain neutral. The ETF maintains strong exposure to Taiwan's semiconductor sector, particularly TSMC, which represents 22.5% of holdings. Recent news highlights Taiwan's strategic position in AI chip manufacturing with companies planning $20 billion in US investments.
The ETF offers exposure to Taiwan's dominant semiconductor industry but faces significant geopolitical risks. Strong AI-driven fundamentals and reasonable tech valuations support upside potential, though China-Taiwan tensions represent a persistent overhang. Institutional interest remains positive with Bank of America increasing its stake by 22.4% in the latest quarter.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →